• Aucun résultat trouvé

Targeting of CXCR4+ Glioblastoma initiating cells with a retargeted oncolytic herpesvirus

N/A
N/A
Protected

Academic year: 2021

Partager "Targeting of CXCR4+ Glioblastoma initiating cells with a retargeted oncolytic herpesvirus"

Copied!
2
0
0

Texte intégral

(1)

No Saved/Submitted Abstracts     1 Targeting of CXCR4+ Glioblastoma initiating cells with a retargeted oncolytic

herpesvirus

Submitted View

Submit abstract for 12th International Oncolytic Virus

Conference, Rochester (MN, USA) 9-12 October 2019

Targeting of CXCR4+ Glioblastoma initiating cells with a

retargeted oncolytic herpesvirus

J SANCHEZ GIL     M LEBRUN     A ALLEGRO     A CHEVIGNE     B ROGISTER     C SADZOT-DELVAUX    

1: Laboratory of Virology and Immunology, GIGA Infection, Inmmunity and Inflammation, University of Liege, Belgium    2: LIH, Luxembourg Institute of Health, Department of Infection and Immunity, Luxembourg    3: Laboratory of Nervous System Disorders and Therapy, GIGA Neurosciences, University of Liege, Belgium    

Multiform Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite improvement of treatments (usually surgical resection followed by radio- and/or chemotherapy), glioblastoma patients have a poor prognosis, mainly due to recurrences of the tumor. It has been recently shown in an orthotopic xenograft model that

ADD A NEW ABSTRACT

1 1 1 2 3 1

Abstract https://iovc.ada.wats-on.co.uk/Members/Abstract.aspx?ID=31

(2)

GBM cells can escape the tumor mass and specifically invade the subventricular zones (SVZ) of the adult brain. This migration is mediated by a CXCL12 gradient that attracts GBM cells, which have been shown to express CXCR4 (one of the two CXCL12 receptors). In addition, these CXCR4+ cells share characteristics with stem cells and are thus

considered as GBM-initiating cells responsible for the recurrences. They appear therefore as a target of choice for therapeutic approaches. Oncolytic Herpes simplex virus (oHSV) has been shown to have potent oncolytic effects against tumor cells of different origin, including GBM. We have engineered a herpesvirus, which specifically targets CXCR4+ cells and is armed with genes inducing the extrinsic or/and intrinsic apoptosis signaling pathways. The specificity and efficacy of these engineered oHSV are currently evaluated in vitro in monolayers and 3D cultures and will be soon characterized in vivo in an orthotopic xenograft model of GBM.

  

Abstract https://iovc.ada.wats-on.co.uk/Members/Abstract.aspx?ID=31

Références

Documents relatifs

Our DEAD-box RNA helicases siRNA library screening in multiple human cell lines consistently identified three RNA helicases (DHX29, DHX35 and RIG-I) for which the knockdown

To confirm our in vitro observations regarding oncolytic activity of VVTK-RR-/GFP, we evaluated the virus for the treatment of NOD Scid mice that bear intraperitoneal

We found that the intercellular transfer of NY-ESO-1 induced by MV sensitizes presenting tumor cells to the cytotoxic activity of the NY67 T cell clone in both models: the

Given that T-Vec is able to induce an antitumor immune response in patients, several phase I clinical trials have started to evaluate the combination of this OV with

replicate, multiply, and spread in a lytic manner in tumor cells (oncolysis), (ii) to trigger the release of PAMPs and TAAs/TANs from dying tumor cells, leading to the activation

Along this line, Dieter and colleagues have shown the existence of three different types of TICs in primary human CRC, among which a rare subset of cells that maintain tumor growth

En effet, elle a pu mettre en évidence la présence du virus dans des cultures de plusieurs semaines de cellules dendritiques stro- males médullaires (CD68 + , CD83 + , Fascine + )

Idempotent intersection type systems were used to characterize strongly normalizing terms of calculi with ES [34, 27] while non-idempotence is used in [10] to prove the